Biogen Reports Quarterly Revenues of $3.1 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Biogen (BIIB) PT Lowered to $311 at RBC Capital
April 25, 2018 7:43 AM EDTRBC Capital lowered its price target on Biogen (NASDAQ: BIIB) to $311.00 (from $316.00) while maintaining a Sector Perform rating.
Analyst Brian Abrahams said Q1 softness stems from Spinraza and seasonality.
... MoreBiogen (BIIB) PT Lowered to $375 at Oppenheimer
April 25, 2018 7:15 AM EDTOppenheimer lowered its price target on Biogen (NASDAQ: BIIB) to $375.00 (from $400.00) while maintaining a Outperform rating.
Analyst Jay Olson commented, "A solid 1Q update addressed investor concerns on multiple fronts with decent financial results featuring an EPS beat of $6.05 vs $5.93E consensus and... More
Piper Jaffray Remains Bullish on Biogen (BIIB) Following 1Q
April 24, 2018 8:48 AM EDTPiper Jaffray reiterated an Overweight rating and $407.00 price target on Biogen (NASDAQ: BIIB) following the company's 1Q earnings report. BIIB posted total revenue of $3,131M, missing consensus $3,152M but beating Piper Jaffray's $3,080M estimate. Non-GAAP EPS of $6.05 easily beat consensus $5.93.
BIIB's anti-CD20... More
